FDA Approves Phase II Trials of Agouron's HIV Protease Inhibitor
LA JOLLA, Calif--Agouron Pharmaceuticals, Inc. has received FDA approval to extend its phase II clinical trials of AG1343, conducted in England, to the United States. Under an investigational new drug application, researchers at the Aaron Diamond AIDS Research Center, New York, and Conant Medical Group, San Francisco, will evaluate alternative daily doses of the oral agent in approximately 30 patients.
LA JOLLA, Calif--Agouron Pharmaceuticals, Inc. has received FDAapproval to extend its phase II clinical trials of AG1343, conductedin England, to the United States. Under an investigational newdrug application, researchers at the Aaron Diamond AIDS ResearchCenter, New York, and Conant Medical Group, San Francisco, willevaluate alternative daily doses of the oral agent in approximately30 patients.
AG1343 is a synthetic chemical compound designed to inhibit HIVprotease--an enzyme that plays an essential role in the replicationof HIV. The trial will determine appropriate doses for use inlarge phase II/III pivotal trials scheduled to start this year.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F7d7dfad7849391f4be3ebd2cf39c24f5369cfcd1-1200x1176.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These results and the lack of systemic toxicity observed with [TTFields] provide patients with a promising new treatment option,” according to Joachim Aerts, MD, an investigator of the phase 3 LUNAR trial (NCT02973789).")
